Inspired by PROTACs, new degraders are emerging that harness endocytosis and autophagy to send a wide array of targets to the lysosome for destruction.
Novel targeted degrader concepts are appearing almost daily. In September, Genentech researchers unveiled a cancer-targeting strategy that uses bispecific antibodies to induce degradation of cell membrane proteins — the latest addition to the fast-growing family of targeted degraders. The very next day, University of California, San Francisco biochemist James Wells published on bispecific antibodies that link cytokine receptors to extracellular and membrane protein targets. (EpiBiologics has licensed the technology.) These and other degraders take different roads, but the destination is the same: the lysosome.
This is a preview of subscription content, access via your institution
Access options
Subscribe to Nature+
Get immediate online access to Nature and 55 other Nature journal
Subscribe to Journal
Get full journal access for 1 year
$99.00
only $8.25 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Buy article
Get time limited or full article access on ReadCube.
$32.00
All prices are NET prices.
About this article
Cite this article
Garber, K. The lysosomal degraders.
Nat Biotechnol (2022). https://doi.org/10.1038/s41587-022-01594-7
-
Published:
-
DOI: https://doi.org/10.1038/s41587-022-01594-7
